Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

novartis slovakia s.r.o., slovensko - cyklosporín - 59 - immunopraeparata

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

novartis slovakia s.r.o., slovensko - cyklosporín - 59 - immunopraeparata

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

novartis slovakia s.r.o., slovensko - karbamazepín - 21 - antiepileptica, anticonvulsiva

Európska únia - slovenčina - EMA (European Medicines Agency)

novartis europharm limited  - brolucizumab - wet macular degeneration - oftalmologiká - beovu je indikovaný u dospelých na liečbu neovascular (mokré) vekom podmienená makulárna degenerácia (amd).

Európska únia - slovenčina - EMA (European Medicines Agency)

novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - astma - drogy obštrukčnej choroby dýchacích ciest, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

Európska únia - slovenčina - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol, mometasone furoate - astma - drogy obštrukčnej choroby dýchacích ciest, - bemrist breezhaler is indicated as a maintenance   treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Európska únia - slovenčina - EMA (European Medicines Agency)

novartis europharm limited - glycopyrronium bromide, indacaterol (acetate), mometasone furoate - astma - drogy obštrukčnej choroby dýchacích ciest, - maintenance treatment of asthma in adults whose disease is not adequately controlled.

Európska únia - slovenčina - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - anémia, kosáčiková bunka - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Európska únia - slovenčina - EMA (European Medicines Agency)

novartis europharm limited  - capmatinib dihydrochloride monohydrate - karcinóm, pľúc bez malých buniek - antineoplastické činidlá - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sandoz pharmaceuticals d.d., slovinsko - tizanidín - 63 - myorelaxantia